Literature DB >> 32875616

Age at Onset of LRRK2 p.Gly2019Ser Is Related to Environmental and Lifestyle Factors.

Theresa Lüth1, Inke R König2, Anne Grünewald1,3, Meike Kasten1, Christine Klein1, Faycel Hentati4, Matthew Farrer5, Joanne Trinh1.   

Abstract

OBJECTIVES: The effect of environmental and lifestyle factors on patients with LRRK2 (leucine-rich repeat kinase 2) p.Gly2019Ser (LRRK2+ /PD+ ) compared to idiopathic PD (iPD) has yet to be thoroughly investigated.
METHODS: In a homogeneous Tunisian Arab Berber population, we recruited 200 idiopathic PD and 199 LRRK2 p.Gly2019Ser mutation carriers, of whom 142 had PD (LRRK2+ /PD+ ) and 57 were unaffected (LRRK2+ /PD- ). Case report form (CRF) questionnaires (motor and non-motor symptoms) including the Geoparkinson Questionnaire were used to assess environmental and lifestyle factors.
RESULTS: In LRRK2+ /PD+ , tobacco use was significantly associated with a later median age at onset (AAO). The median AAO was 60 years (interquartile range = 52-67.25) for tobacco users, compared to 52 years (interquartile range = 45.25-61) for non-users (P = 0.0042 at adjusted α = 0.025). Additionally, we observed an independent but additive effect of black tea consumption and tobacco use.
CONCLUSIONS: Our data suggest that tobacco and black tea have a protective effect on age at onset in LRRK2+ /PD+ .
© 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  LRRK2; age at onset; black tea; environment; modifiers; penetrance; smoking

Mesh:

Substances:

Year:  2020        PMID: 32875616     DOI: 10.1002/mds.28238

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  6 in total

1.  Coffee, smoking and aspirin are associated with age at onset in idiopathic Parkinson's disease.

Authors:  Carolin Gabbert; Inke R König; Theresa Lüth; Beke Kolms; Meike Kasten; Eva-Juliane Vollstedt; Alexander Balck; Anne Grünewald; Christine Klein; Joanne Trinh
Journal:  J Neurol       Date:  2022-03-02       Impact factor: 6.682

Review 2.  A genome on shaky ground: exploring the impact of mitochondrial DNA integrity on Parkinson's disease by highlighting the use of cybrid models.

Authors:  Martin Lang; Anne Grünewald; Peter P Pramstaller; Andrew A Hicks; Irene Pichler
Journal:  Cell Mol Life Sci       Date:  2022-05-05       Impact factor: 9.207

Review 3.  Crosstalk of organelles in Parkinson's disease - MiT family transcription factors as central players in signaling pathways connecting mitochondria and lysosomes.

Authors:  Martin Lang; Peter P Pramstaller; Irene Pichler
Journal:  Mol Neurodegener       Date:  2022-07-16       Impact factor: 18.879

4.  Hunting for Familial Parkinson's Disease Mutations in the Post Genome Era.

Authors:  Steven R Bentley; Ilaria Guella; Holly E Sherman; Hannah M Neuendorf; Alex M Sykes; Javed Y Fowdar; Peter A Silburn; Stephen A Wood; Matthew J Farrer; George D Mellick
Journal:  Genes (Basel)       Date:  2021-03-17       Impact factor: 4.096

Review 5.  The Genetics of Parkinson's Disease and Implications for Clinical Practice.

Authors:  Jacob Oliver Day; Stephen Mullin
Journal:  Genes (Basel)       Date:  2021-06-30       Impact factor: 4.096

6.  LIPAD (LRRK2/Luebeck International Parkinson's Disease) Study Protocol: Deep Phenotyping of an International Genetic Cohort.

Authors:  Tatiana Usnich; Eva-Juliane Vollstedt; Nathalie Schell; Volha Skrahina; Xenia Bogdanovic; Hanaa Gaber; Toni M Förster; Andreas Heuer; Natalia Koleva-Alazeh; Ilona Csoti; Ayse Nazli Basak; Sibel Ertan; Gencer Genc; Peter Bauer; Katja Lohmann; Anne Grünewald; Emma L Schymanski; Joanne Trinh; Susen Schaake; Daniela Berg; Doreen Gruber; Stuart H Isaacson; Andrea A Kühn; Brit Mollenhauer; David J Pedrosa; Kathrin Reetz; Esther M Sammler; Enza Maria Valente; Franco Valzania; Jens Volkmann; Simone Zittel; Norbert Brüggemann; Meike Kasten; Arndt Rolfs; Christine Klein
Journal:  Front Neurol       Date:  2021-08-09       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.